PERFORMANCE HIGHLIGHTS

• The Group posted a consolidated revenue of approximately RMB196.1 million for the six months ended 30 June 2022, representing an increase of approximately 14.1%
• Gross profit increased by 9.9% to RMB86.4 million
• Net profit increased by 13.1% to approximately RMB49.9 million
• The increase in revenue was primarily driven by the surge in revenue generated from the sales of Vigour and Vitality Supplement Pill, Fever-removing and Detoxification Pill and Additional Ingredient Huoxiang Zheng Qi Pill
• Northeast, the PRC remained as the largest contributor (55.7%) to the Group’s total revenue
• The Group has currently established a distribution network for 83 distributors covering about 40 cities in the PRC

Read more: Modern Chinese Medicine Announces Year 2022 Interim Results; Expand distribution network to seize...